AM-1714

AM-1714

Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name 1,9-dihydroxy-3-(2-methyloctan-2-yl)-6H-benzo[c]chromen-6-one
JSmol)	Interactive image
SMILES O=C(O1)C2=C(C=C(O)C=C2)C3=C1C=C(C(C)(C)CCCCCC)C=C3O
InChI InChI=1S/C22H26O4/c1-4-5-6-7-10-22(2,3)14-11-18(24)20-17-13-15(23)8-9-16(17)21(25)26-19(20)12-14/h8-9,11-13,23-24H,4-7,10H2,1-3H3 Key:BWKBVEVEQOCSCF-UHFFFAOYSA-N

AM-1714 (part of the AM cannabinoid series) is a drug that acts as a reasonably selective agonist of the peripheral cannabinoid receptor CB₂, with sub-nanomolar affinity and 490x selectivity over the related CB₁ receptor. In animal studies it has both analgesic and anti-allodynia effects. The 9-methoxy derivative AM-1710 has similar CB₂ affinity but only 54x selectivity over CB₁.^[1][2]

See also

• Cannabinol
• Canbisol

References